Biomai is a tumor immunotherapy drug developer. Its core direction is to develop innovative drug preparations for tumor immunotherapy. It is expected to synergize with existing clinical tumor treatment technologies and significantly enhance its efficacy. At the same time, the company is also targeting Research and development of new tumor interventional therapy technology and new cross-biological barrier macromolecular carrier technology. Recently, Baimai Bio completed tens of millions of yuan in A+ round of financing. This round of financing was exclusively led by Yuansheng Venture Capital. The funds raised will be used to advance clinical trials of new drugs for tumor immunotherapy.
This article is reproduced from: https://www.itjuzi.com/investevent/13529235
This site is for inclusion only, and the copyright belongs to the original author.